Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3683451 | 0.85 | ERN1 (0.38) | CSNK2A1ERN1NPBWR1NT5ESMN1; SMN2 | |
| SCHEMBL3693692 | 0.80 | ERN1 (0.40) | ERN1NPBWR1NT5E | |
| SCHEMBL3688421 | 0.80 | ERN1 (0.36) | ERN1NPBWR1NT5ESMN1; SMN2GRM5 | |
| SCHEMBL1583247 | 0.79 | ERN1 (0.40) | ERN1NPBWR1NT5E | |
| SCHEMBL3695420 | 0.78 | CACNA1H (0.38) | ERN1 | |
| SCHEMBL1583278 | 0.78 | ERN1 (0.40) | ERN1NPBWR1NT5E | |
| SCHEMBL3684681 | 0.78 | ERN1 (0.38) | CSNK2A1ERN1NPBWR1GRM5 | |
| SCHEMBL3694010 | 0.77 | PKM (0.39) | SMN1; SMN2 | |
| Potassium Ion SCHEMBL1583281 | 0.77 | ERN1 (0.39) | ERN1NPBWR1NT5E | |
| Hydrochloric Acid SCHEMBL3787578 | 0.77 | ERN1 (0.38) | CSNK2A1ERN1NPBWR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | CSNK2A1 3746/4885ERN1 237/4885NPBWR1 3024/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | CSNK2A1 3746/4885ERN1 237/4885NPBWR1 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.